E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 12/15/2005 in the Prospect News Biotech Daily.

Charles River maintained by Jefferies at hold

Charles River Lab International was maintained by Jefferies & Co. Inc. analyst David Windley at a hold rating and a $47.50 price target after the company announced slower growth and forecasted non-GAAP earnings per share of $2.46 to $2.52 compared to Jefferies estimate of $2.59 and consensus estimate of $2.57. Due to uncertainty in a couple of key businesses in the third quarter, the company said it was laying out a conservative projection for 2006. Shares of the Wilmington, Mass., drug development services company were up 26 cents, or 0.61%, at $43.01 on volume of 1,686,400 shares versus the three-month running average of 646,085 shares.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.